Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.

Slides:



Advertisements
Similar presentations
Host Defenses, Microbial Evasion & Virulence Factors
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Center for Biologics Evaluation and Research
Hungarian GEnomic Research on pathogenic Microbes Hu-GERM.
Laboratory of Immunobiochemistry Site Visit
Host-Pathogen Interactions. Symbiosis Commensual Mutualistic Parasitic.
Overview of Laboratory of Bacterial Polysaccharides By Willie F. Vann, Chief LBP.
Laboratory of Respiratory and Special Pathogens. History of the Laboratories Laboratory of Pertussis Laboratory of Respiratory and Special Pathogens Laboratory.
The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007.
Pathogenesis. Fig KOCH’S POSTULATES Tools: Diseased animal Healthy animal Red blood cell Observe blood/tissue under the microscope Red blood cell.
Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.
1.1 Pathogens. Starter What is health? A state of complete physical, mental and social well- being. What is disease? A description of symptoms which suggest.
Mechanisms of Pathogenicity Microbiology 2314 Definitions Pathogenicity The ability of a pathogen to produce a disease by overcoming the defenses of.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 25 October 2013.
Overview of the Division of Viral Products
Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.
Overview of the Division of Viral Products VRBPAC Presentation of the Site Visit Report for the Laboratories of Retrovirus Research, Immunoregulation,
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
What Do Toxicologists Do?
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Overview of Laboratory of Bacterial Polysaccharides Willie F. Vann, Ph.D. Chief, Laboratory of Bacterial Polysaccharides.
Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Michael J. Brennan, Ph.D. for Kathryn M. Carbone, M.D. Associate Director for.
Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.
Bacterial Toxins Chapter 14 Add-on.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 28 February 2012.
Infection and Disease II Pathogenicity and Infection.
Sequencing capacitiesacademic company based microarray facilitiesacademic company based bioinformaticsacademic proteomic facilitiesacedemic Genome Research.
FDA Regulation of Bacterial Vaccines
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP.
ERA-NET PathoGenoMics Meeting Bonn 7-8 April, 2005 Research topics of interest in the Area of Genomics of Bacterial and Fungal Pathogens of Humans Prof.
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
Laboratory of Immunobiochemistry site visit Jay E. Slater, MD FDA/CBER/OVRR/DBPAP June 29, 2006.
MICROBES AND MAN Research Programme October 13, 2004 Berlin Soile Juuti Programme manager Finland.
Laboratory of Enteric and Sexually Transmitted Diseases Historical Perspective Origin: Began in Established to review the rapidly increasing.
Pathogenic Bacteria : Transmission, Prevention, and Treatment.
Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.
Small Talk Cell-to-Cell Communication in Bacteria.
Laboratory of Mycobacterial Diseases and Cellular Immunology Center for Biologics Evaluation and Research.
Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP.
A study of Epidemiology
LIB site visit January 24, 2002 Jay E. Slater, MD Laboratory of Immunobiochemistry FDA/CBER/OVRR/DBPAP.
Pathogenesis of bacterial Infections
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
1 Approaches to Demonstrate Effectiveness of Vaccines for Prevention of Group B Meningococcal Disease Introduction Vaccines and Related Biological Products.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Pathway to Licensure for Protective Antigen-based Anthrax Vaccines for a Post-exposure Prophylaxis Indication Using the Animal Rule.
Laboratory of Methods Development and Quality Control Laboratory Overview September 22, 2005.
FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.
OBRR Response to BPAC Recommendations on the Office Research Program Office Site Visit: July 22, 2005 BPAC Recommendations: February 10, 2006 C.D. Atreya,
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
Office of Vaccines Research and Review
Introduction to FDA’s Office of Vaccines Research and Review Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review.
CBER Research: OBRR Office Site Visit Kathryn M. Carbone, MD Associate Director of Research CBER/FDA.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Overview Laboratory of Bacterial Polysaccharides From cover - Science, 23 March, 2001.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
1 Assessment of the Effectiveness of Small Pox Vaccines: Immunogenicity Assay Considerations Freyja Lynn Division of Bacterial, Parasitic and Allergenic.
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
Part II: Reproduction and pathogenic bacteria. Review: Structure of bacteria:
Microbial toxin There are several virulence factors which help to establish disease The virulence of some bacteria is thought to be aided by the production.
Prof. Ramesh Wigneshweraraj
Chapter 15 Microorganisms and Human Disease
Host Parasite Relationship
Presentation transcript:

Division of Bacterial, Parasitic and Allergenic Products OVRR/CBER/FDA

Laboratory Mission and Functions Research Review Post-licensure surveillance –Inspection/compliance –Lot release testing/protocol review –Label/promotional activity review Consultations with outside organizations Assure Safe and Effective Products for Immunological Control of Bacterial, Parasitic and Allergenic Agents Affecting Human Health

DBPAP Role in Regulatory Review and Approval Pre-IND IND License Meeting with sponsors to provide guid- ance Rev. of orig. Submission & all subsequent ammendments Tech. Advice for product and assay development Rev. product manf. data & determin- ation of prod. specs. Meet with sponsors Present prod. To Advisory Comm. Meet with spon- sors Eval. Assays to measure clinical response to prod. Eval. product characterization methods & assays Rev. of final prod. manuf. process, in- cluding in process & final product specs. Est. lot release protocols for CBER product release Conduct pre-approval inspection of the facility

DBPAP Role in Regulatory Review and Approval Pre-IND IND LicensePost Licensure Review of Biological Deviation reports from industry Participation in biannual inspections of licensed products Review of post approval commitments Review of subsequent supplements for changes to maufacture or additional indications Meet with sponsors

Possible New or Improved Products Respiratory Pathogens –Streptococcus pneumoniae –Mycobacterium tuberculosis –Pseudomonas aeruginosa –Neisseria meningitidis A,B,C,Y,W125 –Group B Streptococci –Bordetella pertussis –Chlamydia pneumoniae –Corynbacterium diphtheriae –Non-typeable H. influenzae –Moraxella catarrhalis Sexually Transmitted Pathogens –Neisseria gonorrheae –Chlamydia trachomatis Pathogens Encountered by Penetrating Inoculation –Borrelia burgdorfi –Plasmodium species –Leishmania species –Clostridium tetani –Staphylococcus aureus –Schistosoma species –Trypanosoma cruzi Special Pathogens (BT) –Bacillus anthracis –Clostridium botulinum –Franciscella tularensis –Yersinia pestis

Possible New or Improved Products Diarrhea-Causing Pathogens –Enterotoxigenic E. coli –Shigella species –Vibrio cholerae –Campylobacter jejuni Other Mucosally-Trafficking Pathogens –Clostridium difficile –Salmonella typhi –Mycobacterium leprae –Helicobacter pylori –STEC and EPEC Allergenic Antigens –Latex –Cockroach –Short ragweed Skin Test Antigens –PPD –Coccidioidin –Leishmania

Division of Bacterial, Parasitic and Allergenic Products (DBPAP) Laboratory of Immunobiochemistry Jay Slater, M.D.-Chief Immediate Office of the Director Richard Walker, Ph.D.-Director Milan Blake, Ph.D.-Deputy Director Regulatory Staff Administrative Staff Laboratory of Methods Development and Quality Control Bruce Meade, Ph.D.-Chief Laboratory of Respiratory and Special Pathogens Drusilla Burns, Ph.D.-Chief Laboratory of Bacterial Polysaccharides Milan Blake, Ph.D.- Acting Chief Laboratory of Enteric and Sexually Transmitted Diseases Dennis Kopecko, Ph.D.-Chief Laboratory of Mycobacterial Diseases and Cellular Immunology Sheldon Morris, Ph.D.-Chief Laboratory of Bacterial Toxins Willie Vann, Ph.D.-Chief Laboratory of Biophysics Richard Pastor, Ph.D.-Chief

Laboratory of Methods Development and Quality Control Research activities: Develop and evaluate –Quality control methods for bacterial vaccines –Serological methods for immune response measurement –Animal models Gastrointestinal anthrax Bioassays for potency and toxicity Issues and observations –Recruiting for 1 position –Lab chief

Laboratory of Biophysics Areas of Research Characterization of biopolymers (polysaccharides, proteins DNA) and macromolecular assemblies (vaccine/adjuvant complexes, membranes, micelles). High-end instrumentation, including NMR, light scattering, mass spec. Computer simulation methods for molecular modeling and analysis of complex data. Issues and Observations Integration as CBER high technology resource under review

Laboratory of Bacterial Polysaccharides Areas of Research Characterization of immune responses to polysaccharide and conjugate vaccines Standardization of methods for relevant clinical application Development of novel physical and chemical methods for improved evaluation of licensed and experimental vaccines Characterization of innovative approaches to vaccine development, and evaluation of epidemiologic aspects of vaccine candidates Issues and Observations Polysaccharide immunology group added Mucosal immunity effort recommended Lab go-away to develop focus and transition strategy

LABORATORY OF BACTERIAL TOXINS Areas of Research Neurotoxins Group –Mechanism of toxin entry into nerve cells –Interaction toxin with cellular components –Mechanism of toxin persistence Corynebacteria Group –Identification and characterization of iron regulated virulence factors in C. diphtheria Glycobiology Group –Mechanism of bacterial capsular polysaccharide biosynthesis –Binding of neurotoxins to glycolipid receptors Issues and Observations Development of neurotoxin assays Decreased emphasis on B. anthracis Increased emphasis on vaccine design

Laboratory of Respiratory and Special Pathogens Areas of Research Bordetella pertussis, Bacillus anthracis, and Yersinia spp. Characterization of Virulence Factors and Studies on Mechanism of Action Studies on Regulation of Gene Expression Animal Models of Infection

The Laboratory of Mycobacterial Diseases and Cellular Immunology Areas of Research Evaluation of protective innate and adaptive immune responses to intracellular bacteria Assessment of live attenuated TB vaccine strains and DNA vaccination strategies against tuberculosis Characterization of a unique family of tuberculosis proteins Issues and Observations Malaria effort lacks investigator SVC recommended recruitment of MD with research background in human immune response to study correlations of human and animal responses

Laboratory of Enteric and Sexually Transmitted Diseases Areas of Research Invasion mechanisms of enteric pathogens Genetic regulation of bacterial virulence genes Mucosal immunity, dosing and adjuvants Anthrax and Shigella - Genetic analysis and development of live attenuated Salmonella- vectored vaccines Issues and Observations Mucosal Immunity group added STD work moved to LBP

Laboratory of Immunobiochemistry Areas of Research Allergen structure and function Immunomodulation of allergic responses Chemokines and chemokine receptors in the modulation of immune responses Issues and Observations Cockroach allergen standardization: collaboration with NIAID Increased attention to human T cell responses to allergens role of endotoxin in the safety and efficacy of allergen vaccines human antibody responses to cockroach allergens Decreased emphasis on latex allergens hymenoptera allergens

Promotion Plan

DBPAP Funding Salary and OVHD from FDA base Expendibles and Equipment –General FDA Appropriation Division operating funds Special needs funds Per capita distribution of remainder evenly among staff involved –CT Funds Handled similarly to general appropriation Divided among CT staff –Extramural Funds Go directly to recipient –Year End Funds

Challenges and Realities Facing Researcher/Reviewers Funding levels uncertain from year to year; dependent upon appropriation process Bureaucratic hurdles Timing of workload determined by sponsor submissions, not by CBER

Evaluation Components Review Individual Review Program Comment on Current and Future Directions

DBPAP Program Focus Areas Standardization of Assay Methods for Bacterial, Parasitic and Allergenic Substances –LMDQC, LB, LIB, LP, LESTD, LBT, LRSP, LMDCI Pertussis and Other Toxin-Mediated Diseases –LMDQC, LB, LBT, LRSP Mycobacterial and Other Intracellular parasites –LMDCI Mucosal Pathogenesis and Immunization –LESTD Allergenic Products and Allergenic Diseases –LB, LIB Products to Combat Bioterrorism Agents –LMDQC, LB, LESTD, LBT, LRSP, LMDCI New Technologies for Characterization of Biologics –LB

Laboratory of Methods Development and Quality Control Areas of Research Develop and evaluate –Quality control methods for bacterial vaccines –Serological methods for immune response measurement –Animal models Gastrointestinal anthrax Bioassays for potency and toxicity Issues and Observations Recruiting for 1 position Lab Chief

Bioterrorism Program Research/Review for: –B. anthracis –F. tularensis –Y. pestis –Botulinum toxin Research Areas: –Genetic manipulation and regulation –Virulence factors –Vaccine improvement –Immunologic assay standardization Cutaneous anthrax infection